Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
42 Neuralgia Trials
Power is an online platform that helps thousands of Neuralgia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Suzetrigine for Diabetic Neuropathy
Wichita, KansasThe purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Sensory Abnormalities, Others
1100 Participants Needed
LX9211 for Diabetic Neuropathy
Wichita, KansasThis trial is testing a new drug called LX9211 to see if it can reduce nerve pain in people with diabetes. The drug works by blocking pain signals in the nerves. Researchers want to find out if it is more effective than other treatments. A similar drug was previously tested for similar conditions but its development was halted due to safety concerns.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
416 Participants Needed
Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain
Tulsa, OklahomaTo be eligible for the trial, subjects must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chemotherapy and have no clinical evidence of actively progressive disease.
The trial period will comprise a Screening period (up to 35 Days), randomization and a 4-day treatment period, followed by a 12-week follow up period (12 weeks total after initial treatment), and an End-of-Trial/Follow-up visit which will occur at Week 13. This is a study to research the effects of the study drug on neuropathic pain compared placebo.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:21+
Sex:All
222 Participants Needed
Multiple Treatments for Chronic Pain
Tulsa, OklahomaThis trial is testing different treatments for chronic pain in patients with knee osteoarthritis, chronic low back pain, and diabetic nerve pain. It aims to find effective ways to reduce their chronic pain.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Heart Block, Cancer, Fibromyalgia, Substance Use, Others
10000 Participants Needed
High-Dose vs Low-Dose Capsaicin for Neuropathic Pain
Overland Park, KansasThis is an interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated topical application of Qutenza (capsaicin 8% topical system) versus low-dose capsaicin control (capsaicin 0.04% topical system) in subjects with moderate to severe postsurgical neuropathic pain (PSNP).
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
409 Participants Needed
Halneuron for Neuropathy
Kansas City, MissouriA randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Non-CINP Neuropathic Pain, Prior HAL
200 Participants Needed
LY3556050 for Diabetic Peripheral Neuropathic Pain
Kansas City, MissouriThis trial is testing a new drug called LY3556050 to see if it can help reduce nerve pain in people with diabetes. The study will last several months and will compare the effects of LY3556050 to another treatment. The goal is to determine if LY3556050 is safe and effective for treating diabetic nerve pain.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cancer, HIV, Substance Use Disorder, Others
410 Participants Needed
RTA 901 for Diabetic Neuropathy
Kansas City, MissouriThis trial is testing a new drug called RTA 901 to see if it can help people with nerve pain caused by diabetes. The drug likely works by calming down the nerves that are causing the pain. The study will compare different doses of the drug to find out which dose works best.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Non-diabetic Neuropathy, Fibromyalgia, Diabetic Foot Ulcer, Others
384 Participants Needed
Ultrasound-Guided Ablation for Neuropathic Pain
Kansas City, KansasStudy an ultrasound guided approach to radiofrequency ablation of the occipital nerve that makes it possible to see the needle during treatment procedure. It is hoped this will reduce the amount of pain after the standard of care procedure.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 80
Sex:All
20 Participants Needed
Suzetrigine for Diabetic Neuropathy
Kansas City, MissouriThe purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:18 - 80
Sex:All
300 Participants Needed
NRD135SE.1 for Peripheral Neuropathy
Kansas City, KansasThis trial tests a daily pill called NRD135S.E1 for people with painful nerve damage from diabetes. The study will see if taking this pill for a few months can safely reduce their pain. Researchers aim to understand how well the drug works and if it is safe to use.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
122 Participants Needed
LY3848575 for Neuropathic Pain
West Des Moines, IowaThe purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee.
Participation may last up to 30 weeks including screening.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Diabetes, Cancer, Suicidal, Others
450 Participants Needed
VX-993 for Diabetic Neuropathy
Dallas, TexasThe purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Painful Neuropathy, Cardiac Dysrhythmias, Atherosclerotic Event, Others
Must Not Be Taking:Anti-arrhythmics
300 Participants Needed
GSK3858279 for Diabetic Neuropathy
Red Oak, TexasThis is a multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP). The primary objective of the study is to assess the efficacy of GSK3858279 in participants with DPNP who have been unable to sufficiently manage their pain.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
145 Participants Needed
Ginger for Nerve Pain
Lubbock, TexasNeuropathic pain affects the quality of life of many Americans. Non-pharmacological strategies such as bioactive compounds in foods are being explored as therapeutics but can also serve as tools to better understand pain mechanisms. The previous study reported that ginger root extract supplementation palliated pain-spectrum behaviors in animals with neuropathic pain via the microbiota-gut-brain axis. The proposed study is primarily designed to use ginger supplementation for a better understanding of the role of microbiota-gut-brain interactions in sciatica states in a randomized, double-blinded, and placebo-controlled trial. Eighty participants with sciatica will be randomized to receive placebo (2000 mg starch daily) or ginger (2000 mg daily) for 8 weeks. This study will evaluate the effects of ginger supplementation on gut function measured as gut microbiota composition using 16S rRNA sequencing analysis, intestinal permeability based on plasma lipopolysaccharide binding protein and fecal zonulin using ELISA, and fecal metabolites using LC-MS/MS analysis (SA 1); on neuroinflammation in whole blood mRNA using nCounter® Neuroinflammation Panels analysis (SA 2); and on pain-associated outcomes and brain neuroplasticity by assessing functional (resting state-fMRI) and structural (Diffusion Tensor Imaging) connectivity (SA 3).
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:18 - 85
Sex:All
80 Participants Needed
Axoguard Nerve Cap for Amputation Recovery
Lubbock, TexasThis pilot study evaluates the tolerability and feasibility of the Axoguard Large-Diameter Nerve Cap (sizes 5-7 mm) for protecting and preserving terminated nerve endings after limb trauma or amputation when immediate attention to the nerve injuries is not possible.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Infection, Diabetes, Neuropathy, Others
Must Not Be Taking:Chemotherapy, Radiation, Immunosuppressants, Others
15 Participants Needed
Micro-Implantable Pulse Generator for Chronic Pain
Greenwood Village, ColoradoThis post market study is being conducted to document the comparative effectiveness and safety of peripheral nerve stimulation plus conventional medical management versus conventional medical management alone in the treatment of chronic, intractable peripheral neuralgia of post-traumatic or post-surgical origin. This is a prospective, minimal risk, multi-center, randomized control trial.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 80
Sex:All
89 Participants Needed
Pregabalin + Duloxetine for Peripheral Neuropathy
St. Louis, MissouriThe goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy.
The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC).
This study is a 3-period cross-over trial. This means researchers will compare 3 different drugs (pregabalin, duloxetine, and placebo) over a period of 19 weeks.
Participants will:
* Undergo a quantitative sensory testing (QST) exam.
* Provide a blood sample.
* Complete questionnaires on the computer.
* Take the study drug as instructed.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:18 - 80
Sex:All
190 Participants Needed
Peripheral Nerve Stimulation for Headache
Round Rock, TexasThis trial is testing a device called the SPRINT® PNS System, which sends small electrical signals to nerves in the neck. It aims to help people who suffer from chronic or acute pain. The electrical signals work by blocking pain messages from reaching the brain, potentially reducing pain. This method has been used for decades to treat chronic pain and has seen significant advancements in technology and application in recent years.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Prior Cervical Surgery, Implanted Device, Pregnant
50 Participants Needed
Virtual Walking Therapy for Neuropathic Pain
College Station, TexasThe purpose of this study is to determine if playing a virtual reality walking game can help improve neuropathic pain in adults with incomplete spinal cord injury.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:C1-C4 Injury, Under 18, Recent Injury, Non-English, Prison, Blind, Severe Motion Sickness
48 Participants Needed
Virtual Reality Gaming for Neuropathic Pain
College Station, TexasThe purpose of this study is to determine if playing a virtual reality walking game can help improve neuropathic pain in adults with chronic spinal cord injury.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:C1-C4 Injury, Under 18, Blind, Others
250 Participants Needed
YJ001 Spray for Diabetic Neuropathy
Fredericksburg, TexasThis Phase I, randomized, double-blind and placebo controlled study is to evaluate the safety, tolerability, and PK, and to preliminarily assess the efficacy of topically administered YJ001 in a multiple-ascending dose (MAD) fashion in the patients with DPNP. The study will be conducted at a single study center.
In this study, 2 cohorts (N=24, 12 subjects for each cohort), each cohort will consist of 10 active and 2 placebo, with approximately equal numbers of male and female subjects.
Each subject will be administered a single dose of YJ001 as multiple sprays topically on both feet and below the ankle in the morning on Day 1 and Day 2, and will be administered as twice daily doses once in the morning and the other in the evening (with an interval of 11 to 13 h) from Day 3 through Day 11.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Asthma, Cardiovascular Disease, Alcohol Abuse, Others
Must Be Taking:Antidiabetic Agents
24 Participants Needed
Ketamine Infusion for Neuralgia
Rochester, MinnesotaThis trial is testing if giving ketamine can help reduce severe nerve pain in patients with brachial plexus injuries. Ketamine works by blocking pain signals to the brain. The study aims to see if this reduces the need for other pain medications. Ketamine has been reported to enhance the pain-relieving effects of local anesthetics and is used primarily for patients who are tolerant to opioids and those with severe acute pain.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 4
Age:18+
Sex:All
100 Participants Needed
TSEP + Rhizotomy for Trigeminal Neuralgia
Minneapolis, MinnesotaTrigeminal neuralgia (TGN) is a debilitating pain syndrome where electrical, shock- like jolts of pain affect the face. Trigeminal somatosensory evoked potentials (TSEPs) provide a promising modality for measuring the trigeminal sensory and nociceptive pathway by using peripheral stimulation of the trigeminal nerve (on the skin) and measuring low latency evoked potentials on the scalp (contralateral sensory cortex). While TSEPs have been measured in the past, it is not clear if implementing TSEPs into a routine neurosurgical rhizotomy procedure will be feasible. This is a prospective cohort study examining the feasibility of routinely performing TSEPs during rhizotomies for TGN.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Facial Pain, Migraine, Fibromyalgia, Others
30 Participants Needed
Brivaracetam for Neuropathic Pain in SCI
Minneapolis, MinnesotaThis trial is testing brivaracetam, a medication that may help reduce severe pain in people with spinal cord injuries. It targets a specific protein in the spinal cord that is linked to pain. The study aims to see if this treatment is effective for those who do not respond well to other pain medications.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
40 Participants Needed
Qigong for Spinal Cord Injury
Minneapolis, MinnesotaThis trial tests if Qigong, a practice involving gentle movements and focused breathing, can reduce chronic pain in adults with spinal cord injuries by improving their body awareness and correcting brain function related to pain. Qigong is a therapeutic Chinese practice that has been used for thousands of years to optimize and restore energy (Qi) to the body, mind, and spirit.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Seizures, Cognitive Impairment, Ventilator Dependency, Pregnancy, Others
64 Participants Needed
Spinal Cord Stimulation for Chronic Pain
Houston, TexasThe goal of this study is to compare pain outcomes achieved by spinal cord stimulation (SCS) using time varying stimulation patterns with pain outcomes achieved by current standard of care SCS.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:22+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cancer, Obesity, Infection, Cognitive Impairment, Others
43 Participants Needed
tACS for Neuropathic Pain After SCI
Houston, TexasThe overall goal is to investigate the effectiveness of a novel intervention - transcranial alternating current stimulation (tACS) for neuropathic pain management in people after spinal cord injury.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18 - 75
Sex:All
14 Participants Needed
Ketamine for Nerve Pain and PTSD
San Antonio, TexasThis study is aimed to evaluate outpatient ketamine infusion within a military chronic neuropathic pain population and its effect on PTSD. Currently, this is a pilot study with 30 participants. Participants will be randomized to (1) a moderate dose ketamine, (2) moderate dose ketamine +Mg, or (3) a magnesium control group. Participants will complete self-reported pain and PTSD questionnaires throughout the \~24-week study period. The outlined strategy will provide evidence for the utility of ketamine in neuropathic pain management and pain associated comorbidities within a military population.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Psychosis, TBI, Hypertension, Others
Must Not Be Taking:Theophylline, Benzodiazepines
30 Participants Needed
Cannabis Derivatives for Diabetic Neuropathy
San Antonio, TexasThis trial tests if cannabis derivatives (THC, CBD, and their combination) can reduce chronic diabetic nerve pain in Veterans. Veterans often don't get enough relief from standard treatments, so this study aims to find out if cannabis can help. The trial will test if these cannabis compounds are effective. Cannabis has been studied for its potential to alleviate pain in various conditions, including diabetic neuropathy, but its long-term safety and efficacy remain uncertain.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:21+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cannabis Use Disorder, Psychiatric Disorders, Others
Must Not Be Taking:Cannabis, Opioids
320 Participants Needed
Page 1 of 2+
Frequently Asked Questions
How much do Neuralgia clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Neuralgia clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Neuralgia trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Neuralgia is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Neuralgia medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Neuralgia clinical trials ?
Most recently, we added Pregabalin + Duloxetine for Peripheral Neuropathy, tACS for Neuropathic Pain After SCI and Nerve Interface for Post-Mastectomy Pain to the Power online platform.